ArticleMycopathologia2025
No Evidence for Environmental Triazole Resistance Selection Route in Aspergillus Section Flavi, The Netherlands, 1994-2023.
Article in Mycopathologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
12 authors.
Funding
Abstract
Aspergillus section Flavi comprises opportunistic pathogens such as Aspergillus flavus, posing significant health risks. Unlike A. fumigatus, where environmental selection drives widespread resistance, it is uncertain whether A. flavus develops azole resistance through a similar environmental route. This study analyzed 544 Aspergillus section Flavi isolates collected from 534 patients in Dutch hospitals (1994-2023). Calmodulin sequencing was used for molecular identification. Antifungal susceptibility testing (AFST) was performed according to EUCAST (European Committee on Antimicrobial Susceptibility Testing) guidelines. Cyp51A was sequenced and mutations were mapped onto the CYP 51 protein 3D model for azole-resistant or non-wild-type isolates. Clinical data, including azole exposure history and underlying diseases, were correlated with the resistance profiles. Of the 544 isolates, 520 were identified as A. flavus and 24 as related species, including A. tamarii (16), A. parasiticus (3), A. nomiae (2), A. pseudonomiae (2), and A. pseudocaelatus (1). Fourteen isolates from five patients were azole-resistant/non-WT, with resistance rates ranging from 0.2 to 0.8%. Resistant/non-WT isolates were associated with chronic diseases and prior clinical azole exposure. Among 10 patients with proven/probable invasive aspergillosis azole resistance was not observed. Two main Cyp51A-SNPs were found in azole-resistant isolates: Y119F and T329A. Aspergillus flavus was the dominant pathogenic species within the section Flavi with low levels of azole resistance. Distribution of resistant cases supports in host resistance selection rather than environmental selection. These findings highlight the need for further research on the ecological and molecular factors that influence resistance in A. flavus.
Indexed as
Identifiers
41060349What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.